113 related articles for article (PubMed ID: 29048656)
1. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
2. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract][Full Text] [Related]
3. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
[TBL] [Abstract][Full Text] [Related]
4. A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.
Al-Akhrass H; Conway JRW; Poulsen ASA; Paatero I; Kaivola J; Padzik A; Andersen OM; Ivaska J
Oncogene; 2021 Feb; 40(7):1300-1317. PubMed ID: 33420373
[TBL] [Abstract][Full Text] [Related]
5. [RNPC1 induces sensitivity of HER-2-positive breast cancer BT474 cells to trastuzumab through upregulation of HER2].
Li CL; Zhou XJ; Lou PP; Xia TS; Shi L; Wang Y; Ding Q
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):172-8. PubMed ID: 26988821
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting HER3 Hyperphosphorylation in HER2-Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells.
Villar-Alvarez E; Golán-Cancela I; Pardo A; Velasco B; Fernández-Vega J; Cambón A; Al-Modlej A; Topete A; Barbosa S; Costoya JA; Taboada P
Small; 2023 Dec; 19(50):e2303934. PubMed ID: 37632323
[TBL] [Abstract][Full Text] [Related]
7. HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract][Full Text] [Related]
8. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
Iida M; McDaniel NK; Kostecki KL; Welke NB; Kranjac CA; Liu P; Longhurst C; Bruce JY; Hong S; Salgia R; Wheeler DL
BMC Cancer; 2022 Apr; 22(1):447. PubMed ID: 35461210
[TBL] [Abstract][Full Text] [Related]
9. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
[TBL] [Abstract][Full Text] [Related]
10. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
Xing F; Gao H; Chen G; Sun L; Sun J; Qiao X; Xue J; Liu C
Mol Cancer; 2023 Jan; 22(1):6. PubMed ID: 36627608
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P; Gadewal N; De A
Int J Biol Macromol; 2023 Jul; 242(Pt 2):124765. PubMed ID: 37156315
[TBL] [Abstract][Full Text] [Related]
12. SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs.
Li WJ; Xie CY; Zhu X; Tang J; Wang L; Lou LG
Acta Pharmacol Sin; 2024 Apr; 45(4):857-866. PubMed ID: 38200149
[TBL] [Abstract][Full Text] [Related]
13. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Majumder A; Sandhu M; Banerji D; Steri V; Olshen A; Moasser MM
Sci Rep; 2021 Apr; 11(1):9091. PubMed ID: 33907275
[TBL] [Abstract][Full Text] [Related]
14. NRG1 fusions in breast cancer.
Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
[TBL] [Abstract][Full Text] [Related]
15. ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation.
Nunes J; Zhang H; Angelopoulos N; Chhetri J; Osipo C; Grothey A; Stebbing J; Giamas G
Oncotarget; 2016 May; 7(19):27599-612. PubMed ID: 27050377
[TBL] [Abstract][Full Text] [Related]
16. Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.
Miano C; Romaniello D; Mazzeschi M; Morselli A; Da Pra S; Sacchi F; Bongiovanni C; Sgarzi M; Pantano E; Lauriola M; D'Uva G
Front Oncol; 2022; 12():831105. PubMed ID: 35664762
[TBL] [Abstract][Full Text] [Related]
17. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
Zuo BL; Yan B; Zheng GX; Xi WJ; Zhang X; Yang AG; Jia LT
Cancer Immunol Immunother; 2018 Mar; 67(3):393-401. PubMed ID: 29127433
[TBL] [Abstract][Full Text] [Related]
18. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
19. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.
Amin DN; Ahuja D; Yaswen P; Moasser MM
Mol Cancer Ther; 2015 Dec; 14(12):2805-17. PubMed ID: 26438156
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Noblejas-López MDM; Gandullo-Sánchez L; Galán-Moya EM; López-Rosa R; Tébar-García D; Nieto-Jiménez C; Gómez-Juárez M; Burgos M; Pandiella A; Ocaña A
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
